1. FRI0248 Baseline Data on Patients in Giacta (Tocilizumab in Giant Cell Arteritis). (9th June 2015) Authors: Tuckwell, K.; Collinson, N.; Klearman, M.; Dimonaco, S.; Stone, J.H. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 514 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. OP0002 No difference in the risk of malignancy in tocilizumab versus tnf inhibitor initiators in patients with rheumatoid arthritis: a multi-database cohort study. (12th June 2018) Authors: Kim, S.C.; Pawar, A.; Desai, R.J.; Gale, S.; Klearman, M.; Sarsour, K.; Solomon, D.H.; Schneeweiss, S. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 50 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. OP0237 A comparison of pk and pd outcomes of tocilizumab in giant cell arteritis after sc and iv dosing. (12th June 2018) Authors: Mallalieu, N.L.; Stone, J.H.; Villiger, P.; Klearman, M.; Brockwell, L.; Dimonaco, S.; Charion, J.E. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 167 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. SAT0550 Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial. (12th June 2018) Authors: Strand, V.; Dimonaco, S.; Tuckwell, K.; Klearman, M.; Collinson, N.; Stone, J.H. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 1128 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. SAT0531 Acute phase reactant levels and prednisone doses at disease flare in patients with giant cell arteritis: prospective data from the giacta trial. (12th June 2018) Authors: Stone, J.H.; Tuckwell, K.; Dimonaco, S.; Klearman, M.; Aringer, M.; Blockmans, D.; Brouwer, E.; Cid, M.C.; Dasgupta, B.; Rech, J.; Salvarani, C.; Schulze-Koops, H.; Schett, G.; Spiera, R.; Unizony, S.H.; Collinson, N. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 1120 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. FRI0493 Pet/ct in patients with giant cell arteritis after 1 year of treatment with tocilizumab plus prednisone taper or only prednisone taper. (12th June 2018) Authors: Ishai, A.; Brouwer, E.; Maldini, C.; Stone, J.H.; Espigol-Frigole, G.F.; Cid, M.C.; Blockmans, D.; Carmellino, D.; Cimmino, M.; Muratore, F.; Slart, R.; Salvarani, C.; Narvaez Garcia, F.; De Vita, S.; Hellmich, B.; Dimonaco, S.; Klearman, M.; Petho-Schramm, A.; Tuckwell, K.; Collinson, N. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 774 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. LB0003 Tocilizumab (TCZ) monotherapy is superior to adalimumab (ADA) monotherapy in reducing disease activity in patients with rheumatoid arthritis (RA): 24-week data from the phase 4 adacta trial. (23rd January 2014) Authors: Gabay, C.; Emery, P.; van Vollenhoven, R.; Dikranian, A.; Alten, R.; Klearman, M.; Musselman, D.; Agarwal, S.; Green, J.; Kavanaugh, A. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 152 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. OP0165 Changes in Lipoprotein(A) after Treatment with Tocilizumab (TCZ), Adalimumab (ADA), and Methotrexate (MTX) in Patients with Rheumatoid Arthritis (RA). (10th June 2014) Authors: Gabay, C.; McInnes, I.; Kavanaugh, A.; Tuckwell, K.; Collinson, N.; Klearman, M.; Green, J.; Sattar, N. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 124 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. FRI0377 Classification Criteria for Giant Cell Arteritis: Data from Giacta Informing The Need for Revision. (15th July 2016) Authors: Tuckwell, K.; Collinson, N.; Klearman, M.; Dimonaco, S.; Stone, J.H. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 571 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. FRI0137 Risk factors for major adverse cardiovascular (CV) events (MACE) in rheumatoid arthritis (RA) patients treated with tocilizumab (TCZ). (23rd January 2014) Authors: Rao, V.U.; Pavlov, A.; Klearman, M.; Musselman, D.; Giles, J.T.; Bathon, J.M.; Sattar, N.; Lee, J.S. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 356 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗